Dr. José Luis García Giménez holds a Bachelor's degree in Chemistry (2002), a Bachelor's degree in Biochemistry (2004), and a PhD in Chemistry from the University of Valencia. He is currently an Assistant Professor in the Department of Physiology at the Faculty of Medicine and Dentistry, a Postdoctoral Researcher at CIBER-ISCIII in Rare Diseases, and Principal Investigator of the emerging group in Epigenetics and Translational Epigenomics at INCLIVA.

He has published over 125 scientific articles, 60 presentations at international conferences, and 7 book chapters, with over 3,000 citations. He is the editor-in-chief of the books "Epigenetic Biomarkers and Diagnostics" and "Epigenetics in Precision Medicine" (Academic Press, Elsevier).

Throughout his career, he has participated in 37 funded research projects (15 as Principal Investigator) within the ISCIII, the National Research Plan, and regional projects. He is the inventor of five patent families, notably EP15382319.0 and EP16382509.4, granted in the USA, China, Hong Kong, Japan, and Europe, and transferred to industry. He is a co-author of the SepAsT medical software, registered with the OMPM (M4155197).

He is a founding partner of EpiDisease S.L., the first spin-off company of CIBER-ISCIII and INCLIVA, dedicated to the development of IVD tests based on epigenetic biomarkers. His patent on circulating histones for sepsis received the European Commission's Seal of Excellence (EIC Accelerator Challenge).

He has received nine international awards, including the Leopold Flohé Redox Pioneer Award (2023) and the European Young Investigation Award (2009). His entrepreneurial work has been recognized by the Massachusetts Institute of Technology (LinQ Idea2 Global 2016 and 2017), CaixaImpulse of the Fundació La Caixa and MindtheGap of the Fundación Botín.

Carlos Romá Mateo (Valencia, 1980) is a Biochemist and holds a Ph. D. in molecular biology and genetics. The theme of his doctoral thesis (2004 - 2009, Prince Felipe Research Center and Faculty of Life Sciences, University of Manchester) was the study of protein families involved in cell signaling in the context of cancer, after which he studied the disease of Lafora, a rare type of epilepsy of fatal consequences (2009 - 2013, Institute of Biomedicine of Valencia - CSIC). From there, his research career has been deepening in the field of rare diseases, from the perspective of oxidative stress and epigenetic alterations. Recently, he has initiated a line of research focused on the molecular alterations resulting from cytotoxicity mediated by circulating histones in the context of sepsis. His teaching career began in 2015 at the European University of Valencia, to finally join the Faculty of Medicine and Dentistry of the Universitat de València as professor and researcher since 2017. He has three research periods (six-year periods) recognized by the CNEAI and currently directs the line of research in rare childhood epilepsies in the Laboratory of Pathophysiology of Rare Diseases of the Department of Physiology. He is the coordinator of the Consolidated Group for Teaching Innovation in Narrative Physiology (FISIONARR), where he leads teaching innovation projects based on the use of comics and other audiovisual materials as tools to promote learning in health sciences. In recent years he has been doing many scientific outreach activities, writing in his own blog and in other web pages, performing talks and monologues, as well as participating in all kinds of science dissemination events. He is a writer in Principia, collaborator in Mapping Ignorance, and co-creator and scriptwriter of the bio-science fiction comic The OOBIK proteotype, together with the illustrator Gerardo Sanz, as well as the author of three books about epigenetics, and evolution. Since 2022 he has been the Academic Director of Continuing Education at the University of Valencia, coordinating the university's own degrees and continuing education programs in the Vice-Rectorate for Continuing Education, Teaching Transformation and Employment.